JP2018531939A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531939A5 JP2018531939A5 JP2018517586A JP2018517586A JP2018531939A5 JP 2018531939 A5 JP2018531939 A5 JP 2018531939A5 JP 2018517586 A JP2018517586 A JP 2018517586A JP 2018517586 A JP2018517586 A JP 2018517586A JP 2018531939 A5 JP2018531939 A5 JP 2018531939A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- domain
- scfv
- selectively binds
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021196759A JP7274781B2 (ja) | 2015-10-06 | 2021-12-03 | 治療用化合物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237835P | 2015-10-06 | 2015-10-06 | |
| US62/237,835 | 2015-10-06 | ||
| PCT/US2016/055722 WO2017062604A1 (en) | 2015-10-06 | 2016-10-06 | Therapeutic compounds and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021196759A Division JP7274781B2 (ja) | 2015-10-06 | 2021-12-03 | 治療用化合物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018531939A JP2018531939A (ja) | 2018-11-01 |
| JP2018531939A5 true JP2018531939A5 (https=) | 2019-11-14 |
| JP7461620B2 JP7461620B2 (ja) | 2024-04-04 |
Family
ID=58488527
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517586A Active JP7461620B2 (ja) | 2015-10-06 | 2016-10-06 | 治療用化合物及び方法 |
| JP2021196759A Active JP7274781B2 (ja) | 2015-10-06 | 2021-12-03 | 治療用化合物及び方法 |
| JP2023071386A Active JP7555625B2 (ja) | 2015-10-06 | 2023-04-25 | 治療用化合物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021196759A Active JP7274781B2 (ja) | 2015-10-06 | 2021-12-03 | 治療用化合物及び方法 |
| JP2023071386A Active JP7555625B2 (ja) | 2015-10-06 | 2023-04-25 | 治療用化合物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US11098100B2 (https=) |
| EP (2) | EP3359168A4 (https=) |
| JP (3) | JP7461620B2 (https=) |
| KR (1) | KR102716215B1 (https=) |
| CN (1) | CN108697736A (https=) |
| AU (2) | AU2016336451B2 (https=) |
| BR (1) | BR112018006811A2 (https=) |
| IL (1) | IL258931B (https=) |
| MX (1) | MX389194B (https=) |
| RU (1) | RU2770001C2 (https=) |
| SG (2) | SG10201912792YA (https=) |
| WO (1) | WO2017062604A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113713091A (zh) | 2015-02-06 | 2021-11-30 | 新加坡国立大学 | 工程免疫细胞及其用途和生产方法 |
| MX389194B (es) | 2015-10-06 | 2025-03-20 | Univ Minnesota | Compuestos terapéuticos y métodos. |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| MX386014B (es) | 2016-08-10 | 2025-03-18 | Univ Ajou Ind Academic Coop Found | Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma. |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| US20190038733A1 (en) | 2017-08-10 | 2019-02-07 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| SG11202005557TA (en) * | 2017-12-12 | 2020-07-29 | Macrogenics Inc | Bispecific cd 16-binding molecules and their use in the treatment of disease |
| CU24545B1 (es) * | 2017-12-29 | 2021-09-07 | Ct Ingenieria Genetica Biotecnologia | Péptido antagonista de la actividad de la interleucina-15 |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| WO2020081841A1 (en) | 2018-10-19 | 2020-04-23 | Regents Of The University Of Minnesota | Nk engager molecules and methods of use thereof |
| AU2019366956B2 (en) | 2018-10-23 | 2025-10-30 | Dragonfly Therapeutics, Inc. | Heterodimeric Fc-fused proteins |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| EP3927745A1 (en) * | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| CA3142159A1 (en) * | 2019-05-31 | 2020-12-03 | City Of Hope | Cd33 targeted chimeric antigen receptor modified t cells for treatment of cd33 positive malignancies |
| CA3142483A1 (en) * | 2019-06-12 | 2020-12-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods to treat viral infections |
| CA3150224A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| EP4031565A4 (en) * | 2019-09-16 | 2023-10-25 | Regents of the University of Minnesota | COMPOUNDS AND METHODS FOR IMMUNOTHERAPY |
| EP4041757A4 (en) * | 2019-09-26 | 2024-04-17 | Regents of the University of Minnesota | VIRAL ANTIGEN BINDING NK ENGAGERS COMPOUNDS AND METHODS OF USE |
| WO2021138407A2 (en) * | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| US20230272041A1 (en) | 2020-04-22 | 2023-08-31 | Dragonfly Therapeutics, Inc. | Formulation, Dosage Regimen, and Manufacturing Process for Heterodimeric FC-Fused Proteins |
| WO2021247794A2 (en) * | 2020-06-03 | 2021-12-09 | Regents Of The University Of Minnesota | B7h3-targeting proteins and methods of use thereof |
| US20240317831A1 (en) * | 2021-01-08 | 2024-09-26 | Regents Of The University Of Minnesota | Nk cell engager molecules and methods of use |
| WO2023006082A1 (zh) | 2021-07-30 | 2023-02-02 | 启愈生物技术(上海)有限公司 | 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用 |
| CN116143942A (zh) | 2021-09-09 | 2023-05-23 | 启愈生物技术(上海)有限公司 | 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用 |
| US20250319128A1 (en) * | 2022-05-16 | 2025-10-16 | Northwestern University | Il15-modified car t cells for dual targeting |
| KR20250018388A (ko) * | 2022-05-31 | 2025-02-05 | 온코펩타이드즈 이노베이션 1 아베 | 신규한 폴리펩타이드 |
| AU2023342647A1 (en) | 2022-09-15 | 2025-02-20 | Avidicure Ip B.V. | Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof |
| WO2024064446A2 (en) * | 2022-09-19 | 2024-03-28 | Duke University | Compositions and methods for the enhancement of immune cell activities against cancer |
| CN118909134A (zh) * | 2023-05-06 | 2024-11-08 | 北京新合睿恩生物医疗科技有限公司 | IL-15融合蛋白及其mRNA序列和应用 |
| CN121773132A (zh) * | 2023-05-12 | 2026-03-31 | 克里斯蒂安-阿尔伯特基尔大学 | 用于扩增nk细胞的手段和方法 |
| WO2025191136A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof |
| WO2025191133A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Il-21 muteins, fusion proteins comprising the same and uses thereof |
| WO2025191137A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Conjugates of trop2-specific antigen binding proteins and cytokines |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100432105C (zh) * | 2002-12-17 | 2008-11-12 | 默克专利有限公司 | 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合 |
| JP2006513225A (ja) * | 2002-12-20 | 2006-04-20 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 化学療法剤と組み合わせたリンホトキシンβ受容体因子 |
| CA2511013A1 (en) * | 2002-12-20 | 2004-07-15 | Biogen Idec Ma Inc. | Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof |
| US7803376B2 (en) | 2003-07-24 | 2010-09-28 | Innate Pharma S.A. | Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds |
| US7235641B2 (en) * | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| CA2533753C (en) | 2004-03-19 | 2012-10-16 | Morinaga Milk Industry Co., Ltd. | Drug for cancer therapy |
| CA2600505C (en) | 2005-03-10 | 2016-05-03 | Morphotek, Inc. | Anti-mesothelin antibodies |
| US8993295B2 (en) * | 2006-07-20 | 2015-03-31 | The General Hospital Corporation | Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting |
| EP2111550B1 (en) | 2007-01-26 | 2011-11-30 | University Of Louisville Research Foundation, Inc. | Methods of detecting autoantibodies for diagnosing and characterizing disorders |
| EP2197909A4 (en) * | 2007-08-24 | 2014-12-03 | Univ Minnesota | REAGENTS ON RECIPES |
| EP2211903A4 (en) | 2007-10-17 | 2011-07-06 | Nuvelo Inc | CLL-1 ANTIBODY |
| JP2011511647A (ja) | 2008-02-13 | 2011-04-14 | ダイアックス コーポレイション | 特異的結合対を作製するための改善された方法 |
| EP2332994A1 (en) | 2009-12-09 | 2011-06-15 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Trispecific therapeutics against acute myeloid leukaemia |
| UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| WO2012017522A1 (ja) | 2010-08-03 | 2012-02-09 | 富士通株式会社 | 検証プログラムおよび検証装置 |
| CN107880136B (zh) * | 2010-09-21 | 2021-11-12 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
| CN102251013A (zh) | 2011-02-22 | 2011-11-23 | 北京市肿瘤防治研究所 | 一个识别肿瘤起始细胞的抗体和抗原及其应用 |
| SG195253A1 (en) * | 2011-06-03 | 2013-12-30 | Xoma Technology Ltd | Antibodies specific for tgf-beta |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| WO2013039883A1 (en) | 2011-09-12 | 2013-03-21 | Abbvie Biotherapeutics Inc. | Artificial nk cells and uses thereof |
| WO2013163427A1 (en) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
| US20140072581A1 (en) | 2012-07-23 | 2014-03-13 | Zymeworks Inc. | Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains |
| US9258177B2 (en) * | 2012-08-02 | 2016-02-09 | International Business Machines Corporation | Storing a data stream in a set of storage devices |
| EP3470431A1 (en) | 2012-09-27 | 2019-04-17 | Merus N.V. | Bispecific igg antibodies as t cell engagers |
| EP3447072A3 (en) * | 2013-03-05 | 2019-05-22 | Baylor College of Medicine | Engager cells comprising cd3 scfv and an antigen recognition domain that binds a tumor antigen for immunotherapy |
| US9879081B2 (en) | 2013-06-25 | 2018-01-30 | Samsung Electronics Co., Ltd. | Protein complex, bispecific antibody including the protein complex, and method of preparation thereof |
| US10287354B2 (en) * | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| CA3151221C (en) | 2014-06-30 | 2026-01-13 | Altor Bioscience Corporation | Il-15-based molecules and methods of use thereof |
| MX389194B (es) | 2015-10-06 | 2025-03-20 | Univ Minnesota | Compuestos terapéuticos y métodos. |
| WO2017165464A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| EP3457139A1 (en) | 2017-09-19 | 2019-03-20 | Promise Advanced Proteomics | Antibody-like peptides for quantifying therapeutic antibodies |
| WO2019139888A1 (en) | 2018-01-09 | 2019-07-18 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Compositions and methods for targeting clec12a-expressing cancers |
-
2016
- 2016-10-06 MX MX2018004114A patent/MX389194B/es unknown
- 2016-10-06 BR BR112018006811-0A patent/BR112018006811A2/en not_active Application Discontinuation
- 2016-10-06 US US15/766,067 patent/US11098100B2/en active Active
- 2016-10-06 EP EP16854310.6A patent/EP3359168A4/en not_active Withdrawn
- 2016-10-06 WO PCT/US2016/055722 patent/WO2017062604A1/en not_active Ceased
- 2016-10-06 JP JP2018517586A patent/JP7461620B2/ja active Active
- 2016-10-06 AU AU2016336451A patent/AU2016336451B2/en active Active
- 2016-10-06 EP EP22154076.8A patent/EP4056190A1/en active Pending
- 2016-10-06 SG SG10201912792YA patent/SG10201912792YA/en unknown
- 2016-10-06 KR KR1020187012492A patent/KR102716215B1/ko active Active
- 2016-10-06 SG SG11201802794PA patent/SG11201802794PA/en unknown
- 2016-10-06 CN CN201680071410.2A patent/CN108697736A/zh active Pending
- 2016-10-06 IL IL258931A patent/IL258931B/en unknown
- 2016-10-06 RU RU2018116565A patent/RU2770001C2/ru active
-
2019
- 2019-09-05 US US16/561,627 patent/US20200087369A1/en not_active Abandoned
- 2019-09-05 US US16/561,587 patent/US11098101B2/en active Active
-
2021
- 2021-08-06 US US17/396,127 patent/US12606604B2/en active Active
- 2021-12-03 JP JP2021196759A patent/JP7274781B2/ja active Active
-
2023
- 2023-04-25 JP JP2023071386A patent/JP7555625B2/ja active Active
- 2023-09-25 AU AU2023233318A patent/AU2023233318A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531939A5 (https=) | ||
| JP2021515806A5 (https=) | ||
| CY1124090T1 (el) | Συνθεσεις αντισωματων για τη θεραπεια ογκων | |
| JP2021054859A5 (https=) | ||
| MX2021006389A (es) | Anticuerpo cd3 y uso farmaceutico del mismo. | |
| IL256871B2 (en) | Constructs for bispecific antibodies binding dll3 and cd3 and uses thereof | |
| JP2017114866A5 (https=) | ||
| JP2018052979A5 (https=) | ||
| JP2019535670A5 (https=) | ||
| JP2017048240A5 (https=) | ||
| FI3348571T3 (fi) | Yksidomeeninen vasta-aine ohjelmoitu solukuolema -ligandille (pd-l1) ja siitä peräisin oleva proteiini | |
| EA202191457A1 (ru) | Анти-pd-l1/анти-4-1bb биспецифические антитела и их применения | |
| JP2015527366A5 (https=) | ||
| JP2017506649A5 (https=) | ||
| PE20191546A1 (es) | Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb | |
| ES2570131T3 (es) | Ratones que expresan una cadena ligera de inmunoglobulina híbrida | |
| JP2017504578A5 (https=) | ||
| JP2012519492A5 (https=) | ||
| HK1207398A1 (en) | Cd3 binding polypeptides | |
| PE20091024A1 (es) | Anticuerpos monoclonales que se unen a anexelekto y sus usos | |
| FI3981792T3 (fi) | Pd-1:tä sitovia molekyylejä ja niiden käyttömenetelmiä | |
| TR201910814T4 (tr) | Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri. | |
| WO2019005640A3 (en) | MULTISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING SAME | |
| EP4364809A3 (en) | Cd19 specific chimeric antigen receptor and uses thereof | |
| MX2021003636A (es) | Receptor antigenico quimerico. |